Novartis files patent suit against Biocon over diabetes drug

Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.

In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.

Galvus is one of Novartis' best-selling medicines, achieving $1.2 billion of sales last year.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India’s relief-rescue ops in Nepal are part of Modi’s South Asia strategy

    In reacting with alacrity to the earthquake disaster in Nepal, prime minister Narendra Modi has demonstrated two things.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Taslima Nasreen

Will Saudi sex slavery ever end?

An intriguing news item was published in the Arab world ...

Purnendu Ghosh

Err all right, but hiding is wrong

We are human, and therefore, prone to making mistakes. We ...

Shona Adhikari

Art lovers in India are spoilt for choice

Recent art trends point towards the inclusion of a wider ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture